Corcept Therapeutics (CORT) Long-Term Deferred Tax (2017 - 2026)

Corcept Therapeutics has disclosed Long-Term Deferred Tax across 10 years of filings, most recently posting $181.6 million for Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $181.6 million, up 25.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $181.6 million (up 25.7% YoY), and the FY2025 annual result was $168.2 million, up 28.48% from the prior year.
• Long-Term Deferred Tax came in at $181.6 million for Q1 2026 at Corcept Therapeutics, up from $168.2 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $181.6 million in Q1 2026 to a low of $37.7 million in Q1 2022.
• The 5-year median for Long-Term Deferred Tax is $97.9 million (2024), against an average of $106.2 million.
• Peak annual rise in Long-Term Deferred Tax reached 123.88% in 2022, while the deepest fall reached 1.86% in 2022.
• Corcept Therapeutics' Long-Term Deferred Tax stood at $61.5 million in 2022, then surged by 47.41% to $90.6 million in 2023, then soared by 44.49% to $130.9 million in 2024, then increased by 28.48% to $168.2 million in 2025, then increased by 7.95% to $181.6 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $181.6 million (Q1 2026), $168.2 million (Q4 2025), and $153.0 million (Q3 2025), per Business Quant data.